Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04897412 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)
A Phase 2 study of Subcutaneous Fat, sponsored by Caliway Biopharmaceuticals Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 5
- Study locations
NCT04897412: Completed Phase 2 study of Subcutaneous Fat, sponsored by Caliway Biopharmaceuticals Co..
NCT04897412 is a Phase 2 study of Subcutaneous Fat that has completed, run by Caliway Biopharmaceuticals Co.. The registered enrollment target is 75 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04897412, a Phase 2 study of Subcutaneous Fat, has completed, sponsored by Caliway Biopharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 5
- Study locations
Study Summary
The Stage 2 of this phase 2 study will be a randomized, single-blind, placebo-controlled, parallel, and multiple-dose study to assess the efficacy, safety, and subject satisfaction of CBL-514.
Primary Outcome
The proportion of subjects who lose at least 150 mL of subcutaneous fat as measured by ultrasound from Baseline to follow-up visits compared with placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG CBL-514 Injection
Study Locations (5)
Illinois
- Investigational site 1 - Chicago
Nebraska
- Investigational site 2 - Omaha
Tennessee
- Investigational site 3 - Nashville
Texas
- Investigational site 4 - Austin
Victoria
- Investigational site 5 - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2022-02-14 |
| Est. Completion | 2023-03-22 |
| Phase | Phase 2 |
What the finished NCT04897412 record still lists
NCT04897412 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Subcutaneous Fat appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04897412 lists 5 locations in 5 states (Illinois, Nebraska, Tennessee).
Frequently Asked Questions
What is clinical trial NCT04897412 about?
NCT04897412 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)". The Stage 2 of this phase 2 study will be a randomized, single-blind, placebo-controlled, parallel, and multiple-dose study to assess the efficacy, safety, and subject satisfaction of CBL-514.
What is the current status of trial NCT04897412?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2022-02-14. Estimated completion is 2023-03-22.
What conditions does trial NCT04897412 study?
This clinical trial studies the following conditions: Subcutaneous Fat.
What interventions are being tested in trial NCT04897412?
The interventions under investigation include: Placebo (OTHER), CBL-514 Injection (DRUG).
Who is sponsoring clinical trial NCT04897412?
This trial is sponsored by Caliway Biopharmaceuticals Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04897412 being conducted?
This trial has 5 study locations across Illinois, Nebraska, Tennessee, Texas, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Subcutaneous Fat
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04897412's enrollment target sits among peer trials
75 900th of 2000 higher than 1,081 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI